Business
Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting
Data from six abstracts advancing cannabidiol (CBD) research to be presented, including two abstracts which highlight results from a U.S. caregiver survey
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Data from six abstracts advancing cannabidiol (CBD) research to be presented, including two abstracts which highlight results from a U.S. caregiver survey that provides insight on real-world seizure and non-seizure outcomes in patients taking Epidiolex\n Additional key abstract demonstrates Epidiolex's utility in improving seizure frequency and seizure-free intervals in patients with Tuberous Sclerosis Complex (TSC) as part of post-hoc analysis of a Phase 3 trial\n\n\nDUBLIN, Dec. 1, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including one late-breaking abstract, will be debuted at the upcoming 2021 American Epilepsy Society (AES) annual meeting, which will be held December 3 to 7, 2021 in Chicago, IL. \n\"With the successful integration of GW Pharmaceuticals this year, Jazz is excited to present at the AES meeting for the first time and meet with physicians and patient advocacy groups to better understand patient needs and build on GW's progress in epilepsy,\" said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development and chief medical officer of Jazz Pharmaceuticals. \"The GW cannabinoid platform enhances our neuroscience R&D portfolio and, coupled with our development capabilities, will accelerate our cannabinoid development programs to potentially treat additional neurological conditions. The latest research being presented at AES adds to the body of clinical evidence supporting Epidiolex, as well as survey data from people living with rare forms of epilepsy that provides additional understanding on reduced seizure frequency and improvements in cognition, emotional functioning and executive function following treatment initiation.\"\nEpidiolex, a pharmaceutical formulation of cannabidiol (CBD), is the first prescription, plant-derived cannabis-based medicine approved by the U.S. Food and Drug Administration. It is indicated for the treatment of patients with seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) and tuberous sclerosis complex (TSC) in patients aged 1 year and older.\nPresentation highlights include:\nBECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey Results: Two posters will be presented from the U.S.-based BECOME global out...